Our finding of SON as an upstream regulator of PTBP1 expression particularly highlights the clinical significance of SON, since PTBP1 has been recently shown as an oncogenic splicing factor in GBM as well as other multiple cancer types (e.g., in breast cancer, colorectal cancer, and inflammation-associated cancers). This evidence concerns the gene SLU7 and breast carcinoma.